Kunena - TOPIC: Zepatier - PBAC yes for GT1 but no for GT3

Zepatier - PBAC yes for GT1 but no for GT3

Start
Prev
1
Next
End

DrJames
Topic Author
Offline
Platinum Member

5 years 10 months ago #20968

The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time. [which is a damn pity because Canada disagrees]

YMMV

Last Edit: 5 years 10 months ago by DrJames.

The following user(s) said Thank You: pat1, Gaj, Hieupham, re_roll, Peach

Please Log in or Create an account to join the conversation.

pat1
Offline
Platinum Member

5 years 10 months ago #20974

That is wonderful news for genotypes 4 and 6 including G1's but it seems so very unfair for those with G3. Where is the dislike tab?

gt 1a VL 6m
F2/3 FibroScan - 9KPa in 2011 and 7KPa in 2015
sof/dac 10 December for 12 weeks
pre tx alt 85 ast 51
4 wk alt 34 ast 31 UND <35
8 wk alt 29 ast 32 UND <15
12wk alt 25 ast 25 EOT 3.3.16
SVR24 UND KPa5.3 F0 in normal range
I am well
.forever grateful to fixhepc

Last Edit: 5 years 10 months ago by pat1.

The following user(s) said Thank You: DrJames, Paul-Jarman-facebook, Gaj, re_roll

Please Log in or Create an account to join the conversation.